Aclaris Therapeutics

Aclaris has minimal revenue from licensing and contract research, no approved products and high clinical concentration risk in 2026. Q1 2026 revenue was 2.0 million dollars, net loss was 19.8 million dollars, and the company is guiding multiple catalyst readouts in the next 6 to 12 months.

The prior discontinuation of the MK2 inhibitor zunsemetinib after a Phase 2b RA failure underscores binary risk typical of small‑cap biotech. Until there is replicated efficacy in controlled trials, forward revenue and cash flow are not predictable.